ATE376421T1 - Immunosuppressive wirkungen von pteridinderivativen - Google Patents

Immunosuppressive wirkungen von pteridinderivativen

Info

Publication number
ATE376421T1
ATE376421T1 AT04761485T AT04761485T ATE376421T1 AT E376421 T1 ATE376421 T1 AT E376421T1 AT 04761485 T AT04761485 T AT 04761485T AT 04761485 T AT04761485 T AT 04761485T AT E376421 T1 ATE376421 T1 AT E376421T1
Authority
AT
Austria
Prior art keywords
disorders
derivatives
useful
treatment
pteridine derivatives
Prior art date
Application number
AT04761485T
Other languages
English (en)
Inventor
Mark Waer
Piet Herdewijn
Wolfgang Pfleiderer
Arnaud Marchand
Jonghe Steven De
Original Assignee
4 Aza Ip Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/651,604 external-priority patent/US7276506B2/en
Priority claimed from GB0408955A external-priority patent/GB2413324A/en
Application filed by 4 Aza Ip Nv filed Critical 4 Aza Ip Nv
Application granted granted Critical
Publication of ATE376421T1 publication Critical patent/ATE376421T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04761485T 2003-08-29 2004-08-27 Immunosuppressive wirkungen von pteridinderivativen ATE376421T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/651,604 US7276506B2 (en) 1998-12-28 2003-08-29 Immunosuppressive effects of pteridine derivatives
GB0408955A GB2413324A (en) 2004-04-22 2004-04-22 Pharmaceutically active pteridine derivatives

Publications (1)

Publication Number Publication Date
ATE376421T1 true ATE376421T1 (de) 2007-11-15

Family

ID=34276842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04761485T ATE376421T1 (de) 2003-08-29 2004-08-27 Immunosuppressive wirkungen von pteridinderivativen

Country Status (10)

Country Link
EP (1) EP1658081B1 (de)
AT (1) ATE376421T1 (de)
AU (1) AU2004267885A1 (de)
CA (1) CA2534151A1 (de)
CY (1) CY1107264T1 (de)
DE (1) DE602004009696T2 (de)
DK (1) DK1658081T3 (de)
ES (1) ES2295897T3 (de)
PL (1) PL1658081T3 (de)
WO (1) WO2005021003A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
CA2619365A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2008003149A2 (en) * 2006-07-06 2008-01-10 Gilead Sciences , Inc. Substituted pteridines for the treatment and prevention of viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10144736B2 (en) * 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
CN101569617A (zh) * 2009-06-11 2009-11-04 辽宁利锋科技开发有限公司 具有金刚烷结构药物及其衍生物和类似物抗肿瘤新适应症的应用
EP2713736B1 (de) 2011-06-01 2023-08-02 Janus Biotherapeutics, Inc. Neue immunsystemmodulatoren
CU20180011A7 (es) 2015-03-04 2018-06-05 Gilead Sciences Inc Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
PL3507276T3 (pl) 2016-09-02 2022-02-21 Gilead Sciences, Inc. Związki modulatory receptorów toll-podobnych
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN114984019B (zh) * 2022-07-15 2023-08-22 山东中医药大学 一种铁死亡抑制剂化合物及在肝损伤修复领域的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785353A (en) * 1953-01-30 1957-10-30 Merck & Co Inc Substituted pteridine derivatives
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US3081230A (en) * 1960-09-08 1963-03-12 Smith Kline French Lab Diuretic and antihypertensive triaminoarylpteridines
US3159628A (en) * 1962-05-28 1964-12-01 Smith Kline French Lab Pteridine-5-oxide derivatives
DE1921308A1 (de) * 1969-04-25 1971-01-07 Boehringer Sohn Ingelheim Herzwirksame Zubereitungen
US3859287A (en) * 1971-05-05 1975-01-07 Walter Wesley Parish Thiopteridines and process for producing same
DE3323932A1 (de) * 1983-07-02 1985-01-10 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
DE3445298A1 (de) * 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DD267495A1 (de) * 1987-11-11 1989-05-03 Akad Wissenschaften Ddr Verfahren zur herstellung eines neuen methotrexat-derivates mit verminderter toxizitaet
DE4009941A1 (de) * 1990-03-28 1991-10-02 Thomae Gmbh Dr K Verwendung von pteridinen zur sensibilisierung resistenter plasmodien bei der malaria-chemotherapie und diese verbindungen enthaltende arzneimittel
ES2229803T3 (es) * 1998-12-28 2005-04-16 4 Aza Bioscience Nv Efectos inmunosupresivos de derivados de pteridina.
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SE0003828D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
DE10202468A1 (de) * 2002-01-23 2004-09-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung
DE602004008304T2 (de) * 2003-09-12 2008-05-08 4 Aza Ip Nv Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha

Also Published As

Publication number Publication date
CY1107264T1 (el) 2012-11-21
WO2005021003A2 (en) 2005-03-10
DK1658081T3 (da) 2008-02-25
AU2004267885A1 (en) 2005-03-10
ES2295897T3 (es) 2008-04-16
DE602004009696D1 (de) 2007-12-06
CA2534151A1 (en) 2005-03-10
PL1658081T3 (pl) 2008-03-31
WO2005021003A3 (en) 2005-06-09
EP1658081B1 (de) 2007-10-24
DE602004009696T2 (de) 2008-08-28
EP1658081A2 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
CY1107264T1 (el) Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine
DK1673092T3 (da) Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi
IL185289A0 (en) Substituted pyrido (2,3-d) pyrimidine derivatives useful as medicines for the treatment of autoimmune disorders
WO2006069805A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2009003669A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
BR0316256A (pt) Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
DK1663244T3 (da) Pteridin-derivater til behandling af TNF-alpha-beslægtede sygdomme
DE50311449D1 (de) Verwendung von folaten zur herstellung einer zubereitung geeignet zur vorbeugung und behandlung von ammationsmarker crp und saa
TW200738660A (en) Piperidinyl derivatives as modulators of chemokine receptor activity
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
NO20073113L (no) Indenylderivater og anvendelse derav for behandling av neurologiske lidelser
ATE433966T1 (de) Methylendipiperidinderivate
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
TW200505448A (en) 5-hydroxyindoles with n-oxide groups and the use thereof as therapeutic agents
NO20055517L (no) 4-,6-O 7-hydroksyindoler med N-oksidgrupper og anvendelse av disse som terapeutiske midler
GEAP202316371A (en) Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide
DE602004010186D1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
DE602004025849D1 (de) Behandlung von schwerer aphasie bei chronischen zerebrovaskulären erkrankungen
EP1878728A3 (de) Derivate von Piperazin und dessen höheren Homologen zur Behandlung von Krankheiten, die mit Entzündungen einhergehen
NO20053612L (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1658081

Country of ref document: EP

REN Ceased due to non-payment of the annual fee